ValiRx Share News (VAL)

LONDON (Alliance News) - ValiRx PLC on Tuesday said its lead compound, VAL201, continues to perform well in its phase I/II trial for hormone-resistant prostate cancer.

The life sciences company is integrating additional clinical trial centres into the study to assist with the dose expansion stage of the trial, and it has also begun to design a follow-up full efficacy study of VAL201 in prostate cancer.

In light of "excellent results" shown by the compound and promising pre-clinical evidence of its effect on endometriosis, ValiRx is continuing to design a test for VAL201 in this indication.

Elsewhere, its joint venture with Tangent Reprofiling Ltd, ValiSeek Ltd, has made progress on both its commercial and scientific fronts in the first two quarters of 2016.

Regulatory documentation has been prepared for a phase II efficacy study of VAL401 in non-small cell lung cancer. Clinical grade VAL401 capsules have been manufactured, and a second US patent covering the use of VAL401 in adenocarcinoma has been allowed by the US patent office.

Shares in ValiRx were flat at 9.50 pence Tuesday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2016 Alliance News Limited. All Rights Reserved.